LY3303560 - IV

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer DiseaseAlzheimer's Disease

Phase 1

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

CompletedNCT02754830

Eli Lilly and CompanyAlzheimer's Disease

Start: 2016-04-25End: 2018-07-10Updated: 2023-10-13

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

CompletedNCT03019536

Eli Lilly and CompanyAlzheimer Disease

Start: 2017-01-31End: 2019-06-05Updated: 2023-10-10

Related Papers

Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.

2024-02-2216 citations

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial

Journal of Alzheimer s Disease Reports2023-09-079 citations